ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2474

Impact of Multidomain Disease Presentations on Overall Disease Burden Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

Alexis Ogdie1, Peter Hur 2, Mei Liu 3, Sabrina Rebello 3, Robert McLean 3, Blessing Dube 3, Meghan Glynn 4 and Philip Mease 5, 1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, 3Corrona, LLC, Waltham, MA, 4Corrona, LLC, Waltham, 5Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease with heterogeneous presentations that may involve peripheral arthritis, axial disease, enthesitis, dactylitis, and psoriatic skin and nail disease, either alone or in combination. Prior studies have characterized patients affected in one domain; however, there is limited evidence in understanding the differential impact of multidomain vs single-domain presentations on the overall disease burden in PsA. We aim to compare disease characteristics, quality of life, and work productivity at enrollment among patients with PsA who have multidomain vs single-domain presentations in the Corrona PsA/SpA Registry.

Methods: This study included adult patients with PsA enrolled in the Corrona PsA/SpA Registry between March 2013 and August 2018. Patients were evaluated for the presence of 6 disease domains at enrollment: enthesitis (SPARCC enthesitis count > 0), dactylitis (dactylitis count > 0), peripheral arthritis (PA; tender and/or swollen joint count > 0), nail psoriasis (global nail psoriasis VAS > 0), axial disease (physician-reported presence of spinal involvement, based on clinical judgment and/or radiographs or MRI showing sacroiliitis), and skin disease (BSA > 0%), and were further classified as having multidomain or single-domain disease presentations. Separate multivariable linear regression models evaluated the association of the presence of multidomain presentations with selected PsA disease characteristics, quality of life, and work productivity measures relative to single-domain presentations. Models were adjusted for age, sex, race, BMI, disease duration, and current and prior biologic, conventional synthetic disease-modifying antirheumatic drug, and prednisone use.

Results: Of 2315 patients with PsA enrolled in the Corrona PsA/SpA Registry who had ≥ 1 disease domain presentation, 1698 patients (73.3%) were classified as having multidomain disease presentations and 617 (26.7%) as single-domain presentations. The most common single-domain and multidomain presentations, respectively, were skin disease (12.7%) and PA + skin disease (11.7%). At enrollment, patients with multidomain presentations had higher BMI; shorter disease duration; were more likely to have fibromyalgia, depression, and anxiety; and were more likely to have prior biologic use vs those with single-domain presentations (Table 1). In adjusted analyses, the presence of multidomain presentations was associated with significantly worse patient and physician global assessment of disease, pain, fatigue, HAQ-DI and EQ-5D scores, and work productivity and activity at enrollment (Table 2).

Conclusion: In this US real-world cohort, nearly three-quarters of patients with PsA had multidomain disease presentations, which were associated with worse disease activity, quality of life, and work productivity measures compared with single-domain disease presentations. Assessing all PsA domains is critical for developing a comprehensive management plan and reducing the impact of PsA on patients’ lives.


Disclosure: A. Ogdie, AbbVie, 5, 8, Amgen, 2, 5, 8, BMS, 5, Celgene, 5, 8, Corrona, LLC, 5, Lilly, 5, National Psoriasis Foundation, 2, NIH/NIAMS, 2, Novartis, 2, 5, 7, Pfizer, 2, 5, Rheumatology Research Foundation, 2, Takeda, 5; P. Hur, Novartis, 3, Novartis Pharmaceuticals Corporation, 3, Novartis Pharmaceuticals Corporations, 3; M. Liu, Corrona, LLC, 3; S. Rebello, Corrona, LLC, 3; R. McLean, Corrona, LLC, 3; B. Dube, Corrona, LLC, 3; M. Glynn, Corrona, LLC, 3; P. Mease, Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Genentech, Janssen, Novartis, Pfizer, Roche, UCB, 2, 5, Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB, 8, AbbVie, 2, 5, 8, Abbvie, 2, 5, 8, Abbvie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB, 5, Abbvie, Amgen, Bristol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer, UCB, 8, Abbvie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, UCB, 2, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Leo, Merck, Novartis, Pfizer and UCB., 5, 8, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Leo, Eli Lilly, Merck, Novartis, Pfizer, Sun Pharmaceutical Industries, Inc., and UCB, 2, Abbvie, Amgen, Brsitol Myers Squibb, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB, 5, Abbvie, Amgen, Brsitol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer, UCB, 8, Abbvie, Amgen, Brsitol Myers Squibb,Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, UCB, 2, Amgen, 2, 5, 6, 8, Amgen, Bristol-Myers Squibb, Celgene, Galapagos, Gilead, GSK, Janssen, Leo, Eli Lilly, Merck, Novartis, Pfizer, Sun Pharmaceutical Industries, and UCB, 5, BMS, 2, 5, 8, Boehringer Ingelheim, 2, 5, Boerhinger Ingelheim, 5, Bristol Myers Squibb, 2, 5, 8, Bristol Myers Squibb Co., 2, 5, 8, Bristol-Myers Squibb, 2, 5, 6, 8, Celgene, 2, 5, 6, 8, Celgene Corp., 2, 5, 8, CORRONA, 5, Eli Lilly, 2, 5, 8, Galapagos, 2, 5, 8, Genentech, 2, 5, 6, 8, Gilead, 2, 5, 8, Janssen, 2, 5, 6, 8, Janssen Inc, 2, 5, 8, Leo, 2, 5, 8, Lilly, 2, 5, 6, 8, Merck, 2, 5, 8, Novartis, 2, 5, 6, 8, Pfizer, 2, 5, 8, Pfizer Inc, 2, 5, 6, Sun, 2, 5, SUN, 2, 5, Sun Pharma, 2, 5, Sun Pharmaceutical Industries, 2, 5, Sun Pharmaceutical Industries, Inc., 2, 5, 8, UCB, 2, 5, 6, 8, UCB Pharma, 2, 5, 8.

To cite this abstract in AMA style:

Ogdie A, Hur P, Liu M, Rebello S, McLean R, Dube B, Glynn M, Mease P. Impact of Multidomain Disease Presentations on Overall Disease Burden Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/impact-of-multidomain-disease-presentations-on-overall-disease-burden-among-patients-with-psoriatic-arthritis-results-from-the-corrona-psoriatic-arthritis-spondyloarthritis-psa-spa-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-multidomain-disease-presentations-on-overall-disease-burden-among-patients-with-psoriatic-arthritis-results-from-the-corrona-psoriatic-arthritis-spondyloarthritis-psa-spa-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology